Hydration Pharmaceuticals (ASX:HPC), the company behind Hydralyte in North America, is a small holding for Saville Capital as it works toward profitability. In June 2025, Saville Capital reported a positive trading update, with May sales up 34% on April and 18% on the prior year, along with improving gross margins. Saville had earlier noted strong growth in its Liver Detox product and an ongoing focus on cost control, driving rising monthly EBITDA and supporting its path to profitability. Hydration Pharmaceuticals operates in the Consumer Staples sector within the Personal Products industry, and Thesis Tracker has captured 2 comments from 1 fund manager, Saville Capital. Founded in 2017 and headquartered in Cremorne, Melbourne, The Hydration Pharmaceuticals Company markets and distributes oral rehydration and wellness products, including the Hydralyte brand, through retailers and online channels in the United States and Canada, and has expanded its product range into adjacent health categories.